Show simple item record

dc.contributor.authorOlszanski, A
dc.contributor.authorGonzalez, R
dc.contributor.authorCorrie, P
dc.contributor.authorPavlick, A
dc.contributor.authorMiddleton, M
dc.contributor.authorLorigan, Paul C
dc.contributor.authorPlummer, R
dc.contributor.authorSkaria, S
dc.contributor.authorHerbert, C
dc.contributor.authorGore, M
dc.contributor.authorAgarwala, S
dc.contributor.authorDaud, A
dc.contributor.authorZhang, S
dc.contributor.authorBahamon, B
dc.contributor.authorRangachari, L
dc.contributor.authorHoberman, E
dc.contributor.authorKneissl, M
dc.contributor.authorRasco, D
dc.date.accessioned2017-11-22T21:41:02Z
dc.date.available2017-11-22T21:41:02Z
dc.date.issued2017-09
dc.identifier.citation410P Phase I study of the investigational, oral pan-RAF kinase inhibitor TAK-580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): final analysis. 2017, 28(suppl_5): Ann Oncolen
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.doi10.1093/annonc/mdx367.043
dc.identifier.urihttp://hdl.handle.net/10541/620668
dc.language.isoenen
dc.relation.urlhttp://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx367.043/4108632/410PPhase-I-study-of-the-investigational-oralen
dc.rightsArchived with thanks to Annals of Oncologyen
dc.title410P Phase I study of the investigational, oral pan-RAF kinase inhibitor TAK-580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): final analysis.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDepartment of Medical Hematology/Oncology, Fox Chase Cancer Center,en
dc.identifier.journalAnnals of Oncologyen


This item appears in the following Collection(s)

Show simple item record